“Safety of Long-Term Proactive Management With Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial”. SKIN The Journal of Cutaneous Medicine 4, no. 5 (September 2, 2020): s31. Accessed May 22, 2026. https://skin.dermsquared.com/skin/article/view/980.